We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Virus Linked to Aggressive Breast Cancers

By Biotechdaily staff writers
Posted on 21 Jul 2004
Nearly three-quarters of a small sample of Tunisian breast cancer patients showed evidence of a virus similar to one known to cause breast cancer in mice, according to a study published in the July 12, 2004, issue of Cancer.

This is twice the rate seen in women in the United States. More...
Although viruses are known to play a primary role in the development of several human cancers, such as the T cell lymphotropic virus and adult T cell leukemia/lymphoma or herpes virus 8 (HHV8) and Kaposi sarcoma (KS), geographic variability has been noted. For example, KS and HHV8 are least common in the United States and more common in the Mediterranean and Central African regions.

Previous analyses of human breast tissue found viral sequences from the mouse mammary tumor virus (MMTV) in a large percentage of breast cancers but not in normal tissue. MMTV may be spread by a species of house mouse very common in North Africa but not in the United States.

Researchers compared 38 breast tumors from Tunisian patients with samples from several other countries. A significantly higher proportion of samples from Tunisia tested positive for an MMTV-specific genetic sequence, compared to samples from North America. While 74% of Tunisian samples tested positive, other studies reported only 36% from the United States, 38% from Italy, 42% from Australia, and 31% from Argentina. Further analyses revealed that 89% of the MMTV-positive samples were from clinically and histologically aggressive tumors.

"These findings provide increasing evidence for a human breast cancer virus with geographic differences in prevalence,” concluded the authors. The study was conducted by Dr. Paul H. Levine from the George Washington University School of Public Health and Health Services (Washington, DC, USA; www.gwumc.edu) and his colleagues.





Related Links:
George Washington Univ. School of Public Health

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.